Talphera (TLPH) Other Non-Current Liabilities (2010 - 2026)
Talphera's (TLPH) quarterly Other Non-Current Liabilities came in at $1.2 million in Q1 2026, up 31.02% year-on-year from $880000.0 in Q1 2025, and down 51.47% quarter-over-quarter from $2.4 million in Q4 2025.
Talphera (TLPH) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Talphera's Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 31.02% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 31.02% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 123.94% from the prior year.
- Other Non-Current Liabilities slipped to $1.2 million in Q1 2026 per TLPH's latest filing, from $2.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $84.6 million in Q1 2022 and bottomed at $759000.0 in Q2 2025.
- The 5-year median for Other Non-Current Liabilities is $1.9 million (2025), against an average of $8.5 million.
- Across the five-year window, Other Non-Current Liabilities jumped 46648.62% in 2022 and slumped 97.89% in 2023, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $7.1 million in 2022, then tumbled by 74.95% to $1.8 million in 2023, then sank by 40.33% to $1.1 million in 2024, then surged by 123.94% to $2.4 million in 2025, then plunged by 51.47% to $1.2 million in 2026.
- Per Business Quant, the three latest TLPH Other Non-Current Liabilities figures stand at $1.2 million (Q1 2026), $2.4 million (Q4 2025), and $1.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 2.38 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 759,000.00 |
| Mar 31, 2025 | 880,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 7.10 Mn |
| Mar 31, 2022 | 84.62 Mn |
| Dec 31, 2021 | 85.29 Mn |
| Sep 30, 2021 | 109,000.00 |
| Jun 30, 2021 | 128,000.00 |
| Mar 31, 2021 | 181,000.00 |
| Dec 31, 2020 | 88.37 Mn |
| Sep 30, 2020 | 506,000.00 |
| Jun 30, 2020 | 591,000.00 |